Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Cinieri, Saverio; Chan, Arlene; Altundag, Kadri; Vandebroek, An; Tubiana-Mathieu, Nicole; Barnadas, Agusti; Dodyk, Patricia; Lazzarelli, Silvia; Botha, Michiel; Rauch, Daniel; Villanova, Gustavo; Coskun, Ugur

doi:10.1016/j.clbc.2016.06.014

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Cinieri S., Chan A., Altundag K., Vandebroek A., Tubiana-Mathieu N., Barnadas A., ...Daha Fazla

CLINICAL BREAST CANCER, cilt.17, sa.2, ss.91-99, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 2
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.clbc.2016.06.014
Dergi Adı: CLINICAL BREAST CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.91-99
Hacettepe Üniversitesi Adresli: Evet

Özet

This randomized phase II trial compared first-line all-oral vinorelbine/capecitabine, gemcitabine/paclitaxel, and gemcitabine/docetaxel for HER2-negative metastatic breast cancer. Disease control rates (primary end point) were 73%, 78%, and 80%, respectively; median progression-free survival was 7.6, 9.0, and 11.4 months; median overall survival was 30 to 31 months with all regimens. All-oral vinorelbine/capecitabine is an active first-line regimen, and avoids alopecia and frequent intravenous administrations.